Studying antiepileptic drugs in elderly patients
Population Pharmacokinetics, Effectiveness and Safety of Antiepileptic Drugs in Elderly Patients
This study is testing how well different epilepsy medications work and are tolerated in older adults aged 65 and up to find the best dosages for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 65 Years to 100 Years |
| Sex | All |
| Sponsor | Shandong University Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT05459597 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the population pharmacokinetics, effectiveness, and safety of various antiepileptic drugs, including phenytoin, carbamazepine, lamotrigine, levetiracetam, and parempanel, specifically in elderly patients aged 65 and older. The study will analyze how these medications perform in this age group to recommend optimized dosage regimens. By focusing on elderly patients diagnosed with epilepsy who are currently using these medications, the research seeks to enhance treatment outcomes and minimize adverse effects.
Who should consider this trial
Good fit: Ideal candidates for this study are elderly patients aged 65 and older who have been diagnosed with epilepsy and are currently using antiepileptic medications.
Not a fit: Patients who are expected to die within 48 hours or have allergies to antiepileptic drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved dosing strategies for antiepileptic drugs in elderly patients, enhancing their safety and effectiveness.
How similar studies have performed: While there have been studies on antiepileptic drugs, this specific focus on elderly patients and their pharmacokinetics is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥65 years old; 2. Diagnosed with epilepsy; 3. Using antiepileptic drugs for treatment; Exclusion Criteria: 1. Patients who are expected to die within 48 hours; 2. Patients with allergy to antiepileptic drugs; 3. Patients receiving other investigational drugs; 4. Other factors that the researcher considers unsuitable for inclusion.
Where this trial is running
Jinan, Shandong
- Wei Zhao — Jinan, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Wei Zhao
- Email: zhao4wei2@hotmail.com
- Phone: 86053188383308
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.